Literature DB >> 8390278

Lack of effect of enalaprilat on the action of vasoactive intestinal polypeptide in the human forearm.

J R Cockcroft1, P Chowienczyk, T G Elliott, J M Ritter.   

Abstract

It has been proposed that angiotensin converting enzyme (ACE) may play a role in the metabolism of the vasodilator peptide vasoactive intestinal polypeptide (VIP). Reduced metabolism following treatment with ACE inhibitors may cause accumulation of VIP which in turn may mediate some of the beneficial haemodynamic effects of ACE inhibition observed in patients with heart failure. This study has shown that inhibition of local vascular ACE does not interfere with the vascular effects of VIP on forearm resistance vessels when this peptide is infused into the brachial artery of normal volunteers. These results suggest that endothelial ACE plays little part in the metabolism of intravascular VIP.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8390278      PMCID： PMC1381691          DOI： 10.1111/j.1365-2125.1993.tb04179.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN： 0306-5251            Impact factor:   4.335


  9 in total

1.  Reactions of the blood vessels of the human forearm to increases in transmural pressure.

Authors:  A D GREENFIELD; G C PATTERSON
Journal:  J Physiol       Date:  1954-09-28       Impact factor: 5.182

2.  The measurement of volume changes in human limbs.

Authors:  R J WHITNEY
Journal:  J Physiol       Date:  1953-07       Impact factor: 5.182

3.  Increase in vasoactive intestinal polypeptides (VIP) by the angiotensin converting enzyme (ACE) inhibitor lisinopril in congestive heart failure. Relation to haemodynamic and hormonal changes.

Authors:  L Woie; K Dickstein; B Kaada
Journal:  Gen Pharmacol       Date:  1987

4.  Local inhibition of converting enzyme and vascular responses to angiotensin and bradykinin in the human forearm.

Authors:  N Benjamin; J R Cockcroft; J G Collier; C T Dollery; J M Ritter; D J Webb
Journal:  J Physiol       Date:  1989-05       Impact factor: 5.182

5.  Hydrolysis of bradykinin by angiotensin-converting enzyme.

Authors:  F E Dorer; J R Kahn; K E Lentz; M Levine; L T Skeggs
Journal:  Circ Res       Date:  1974-06       Impact factor: 17.367

6.  Peptide histidine valine: its haemodynamic actions and pharmacokinetics in man differ from those of vasoactive intestinal peptide and peptide histidine methionine.

Authors:  J S Gill; Y Yiangou; D J Webb; L Meleagros; N Benjamin; B J Chrysanthou; J R Cockcroft; R C Causon; A J Camm; S R Bloom
Journal:  Clin Sci (Lond)       Date:  1990-05       Impact factor: 6.124

7.  Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.

Authors:  M A Cascieri; H G Bull; R A Mumford; A A Patchett; N A Thornberry; T Liang
Journal:  Mol Pharmacol       Date:  1984-03       Impact factor: 4.436

8.  Immunohistochemical localization and vascular effects of vasoactive intestinal polypeptide in skeletal muscle of the cat.

Authors:  J Järhult; P Hellstrand; F Sundler
Journal:  Cell Tissue Res       Date:  1980       Impact factor: 5.249

9.  The amino acid composition of hypertensin II and its biochemical relationship to hypertensin I.

Authors:  K E LENTZ; L T SKEGGS; K R WOODS; J R KAHN; N P SHUMWAY
Journal:  J Exp Med       Date:  1956-08-01       Impact factor: 14.307
  9 in total
  1 in total

1.  Effects of neuropeptide Y and vasoactive intestinal peptide on human venous smooth muscle in vivo.

Authors:  M Wolzt; W Gerschlager; B Zweytick; B Jilma; H Riemer; K Sertl; H G Eichler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-08       Impact factor: 3.000
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.